NEWS

New TB drugs being tested in India

Friday, March 1, 2013

New Delhi: Research institutes in the country are undertaking trials to test new drugs to treat tuberculosis including the drug-resistant variety, Health Minister Ghulam Nabi Azad said on Friday.

Indian research institutions are undertaking trials to test drugs, including Bedaquiline, Delamanid and PA-824, to treat both drug sensitive and resistant TB, Azad said replying to a question by MP H K Dua during a Rajya Sabha session.

He said the National Institute of Research in TB, Chennai, and All India Institute of Medical Sciences, New Delhi, were part of global trials for new TB drug Bedaquiline (TMC207).

Azad said no application under the drugs and cosmetic rules had been received by the Drug Controller General of India (DCGI) for the grant of permission for any drug from the United States.

A new drug can only be introduced in the Indian market after due approval from the DCGI.

The minister said at present, the replacement of drugs used under the Revised National Tuberculosis Control Programme was not required.

Those patients who suffer from drug-resistant TB are treated with a regime containing drugs to which the TB bacillus was not resistant, he said. [IANS]

Categories: NEWS

Tags: , , , , , , , , , , ,

  More from NEWS

Indian pharmaceutical market to reach $56 billion in 2020


India’s ‘first women hospital’ inaugurated in Delhi


Ability to provide sight being shifted from corneal surgeries to newer technologies


Govt may reduce seats in surgical super-speciality courses that fail to attract doctors


New AI able to identify & predict development of cancer symptom clusters


Humira approved in Japan for treatment of Hidradenitis Suppurativa

Comments »

No comments yet.

Name (required)
E-mail (required - never shown publicly)
URI
Your Comment (smaller size | larger size)
You may use <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong> in your comment.